Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.

@article{Contini1994ActivityOT,
  title={Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.},
  author={C. Contini and M. Manganaro and R. Romani and S. Tzantzoglou and I. Poggesi and V. Vullo and S. Delia and C. De Simone},
  journal={The Journal of antimicrobial chemotherapy},
  year={1994},
  volume={34 5},
  pages={
          727-35
        }
}
The antiprotozoan and antifungal agent, the terbinafine, was investigated for its potential activity against Pneumocystis carinii infection of the A549 cell line culture and on immunosuppressed Sprague Dawley rats in comparison with trimethoprim-sulphamethoxazole and pentamidine isethionate. Terbinafine suppressed P. carinii growth at doses up to 3 g/L within 24 h and it was able to inhibit cyst forms at 60 h post inoculation. With respect to trimethoprim-sulphamethoxazole and pentamidine… Expand
Evaluation of Terbinafine Activity on Pneumocystis carinii in the Rat Model
TLDR
In this model, the efficacy of terbinafine in PCP has been found to be dose dependent and reduced the log number of cysts per gram to 2.5. Expand
Employment of terbinafine against Pneumocystis carinii infection in rat models
The anti‐Pneumocystis carinii response of terbinafine together with that of three other compounds, trimethoprim sulphamethoxazole (TMP‐SMX), atovaquone (ATQ) and albendazole (ALB), has beenExpand
Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
TLDR
Terbinafine was shown to target two specific major antigens, particularly those of 116 and 35-40 kDa, which could be related to disease severity and could provide additional information for monitoring the efficacy of this treatment. Expand
In Vitro and In Vivo Effects of Quinupristin-Dalfopristin against Pneumocystis carinii
TLDR
It is concluded that Q-D has activity against P. carinii in vitro and in vivo, and reduced the organism burden up to 15- and 302-fold, respectively, in immunosuppressed mice. Expand
Terbinafine: a pharmacological and clinical review
TLDR
Terbinafine has established itself as a drug of choice for dermatophytic infections; it must be considered in combination with other antifungal agents for the management of nondermatophytic refractory or resistant yeast/mold infections as well. Expand
Use of Terbinafine in Mouse and Rat Models of Pneumocystis carinii Pneumonia
TLDR
In the present study, terbinafine administered orally at doses of 20 to 400 mg/kg/day and 50 to 250 mg/ kg/day was ineffective therapy for mouse and rat models of pneumocystosis, respectively, emphasize the complexities of P. carinii drug testing and the need for caution before considering studies in humans. Expand
In-vitro activity of atovaquone, sulphamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.
TLDR
Atovaquone, dapsone and sulphamethoxazole were found to be effective at levels well below the concentrations that could be achieved clinically, while DHFR inhibitors were shown to combine effectively with daps one and sulphAMethoxzole. Expand
The Lipids of Pneumocystis carinii
  • E. Kaneshiro
  • Biology, Medicine
  • Clinical Microbiology Reviews
  • 1998
TLDR
Initial studies on the uptake and metabolism of lipids by P. carinii suggest that the organism relies heavily on exogenous lipid nutrients, and development of low-toxicity drugs that prevent sterol C-24 alkylation and the specific inhibition of the lipoxygenase that forms cis-9,10-epoxystearic acid might prove fruitful. Expand
Treatment of Infection Due toPneumocystis carinii
  • J. Fishman
  • Biology, Medicine
  • Antimicrobial Agents and Chemotherapy
  • 1998
TLDR
Treatment of Pneumocystis should be successful if a 14- to 21-day course of therapy is tolerated and the risk of opportunistic infection may be reduced by decreasing the level of immune suppression in patients receiving exogenous immune suppression for autoimmune diseases or following organ transplantation or by reducing the viral load in patients infected with human immunodeficiency virus (HIV). Expand
Inhibitors of Sterol Biosynthesis and Amphotericin B Reduce the Viability of Pneumocystis carinii f. sp.carinii
TLDR
Inhibitors of P. carinii viability as determined by quantitation of cellular ATP levels in a population of organisms varied in inhibitory effect; the most effective included drugs targeted at squalene synthase,Squalene epoxide-lanosterol cyclase, and Δ8 to Δ7isomerase. Expand
...
1
2
3
...